ARWR says ploza(s)iran robust in Phase 3 sHTG trial
ARWR says ploza(s)iran showed robust efficacy and safety in Phase 3 sHTG trials, supporting global regulatory filings.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.